These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 16601284

  • 1. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [Abstract] [Full Text] [Related]

  • 2. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2006 May 14; 71(10):1435-48. PubMed ID: 16530734
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
    Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H.
    World J Gastroenterol; 2006 Sep 21; 12(35):5635-43. PubMed ID: 17007015
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.
    Cancer Res; 2005 May 01; 65(9):3868-76. PubMed ID: 15867386
    [Abstract] [Full Text] [Related]

  • 6. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF.
    Br J Haematol; 2008 May 01; 141(4):470-82. PubMed ID: 18341634
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.
    Eur J Cancer; 2008 Jul 01; 44(11):1577-86. PubMed ID: 18445520
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W.
    J Pathol; 2008 Dec 01; 216(4):428-39. PubMed ID: 18855347
    [Abstract] [Full Text] [Related]

  • 9. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R.
    Anticancer Drugs; 2009 Apr 01; 20(4):259-66. PubMed ID: 19240643
    [Abstract] [Full Text] [Related]

  • 10. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Jänne PA, Saijo N, Minami H.
    Cancer Lett; 2009 Sep 08; 282(1):14-24. PubMed ID: 19345478
    [Abstract] [Full Text] [Related]

  • 11. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
    Int J Oncol; 2008 Nov 08; 33(5):1107-13. PubMed ID: 18949375
    [Abstract] [Full Text] [Related]

  • 12. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
    Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM.
    Leukemia; 2007 May 08; 21(5):886-96. PubMed ID: 17361225
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.
    Gynecol Oncol; 2006 Feb 08; 100(2):389-96. PubMed ID: 16300820
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Attias-Geva Z, Bentov I, Fishman A, Werner H, Bruchim I.
    Gynecol Oncol; 2011 May 01; 121(2):383-9. PubMed ID: 21295335
    [Abstract] [Full Text] [Related]

  • 15. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.
    Int J Oncol; 2012 May 01; 40(5):1659-67. PubMed ID: 22246317
    [Abstract] [Full Text] [Related]

  • 16. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H.
    Endocr Relat Cancer; 2006 Dec 01; 13(4):1237-50. PubMed ID: 17158768
    [Abstract] [Full Text] [Related]

  • 17. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y, Li R, Yamamoto H, Min Y, Piao W, Wang Y, Imsumran A, Li H, Arimura Y, Lee CT, Imai K, Carbone DP, Shinomura Y.
    Carcinogenesis; 2009 Aug 01; 30(8):1305-13. PubMed ID: 19493905
    [Abstract] [Full Text] [Related]

  • 18. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
    Bao XH, Takaoka M, Hao HF, Wang ZG, Fukazawa T, Yamatsuji T, Sakurama K, Sun DS, Nagasaka T, Fujiwara T, Naomoto Y.
    Anticancer Res; 2012 Jul 01; 32(7):2827-34. PubMed ID: 22753744
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2007 May 01; 73(9):1308-17. PubMed ID: 17266941
    [Abstract] [Full Text] [Related]

  • 20. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.